What is the fair value of Nanobiotix (NASDAQ-NBTX) stock?

The current fair value estimate for Nanobiotix (NASDAQ-NBTX) is $26.76. This implies an estimated downside of 30.7% versus the current market price.

Is Nanobiotix (NASDAQ-NBTX) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 30.7% versus the current market price.

What is the analyst price target for NASDAQ-NBTX stock?

The available analyst price target for Nanobiotix (NASDAQ-NBTX) is $43.78. The analyst target implies estimated upside of 13.4%.

How is the financial health of Nanobiotix?

The current financial health read for Nanobiotix (NASDAQ-NBTX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Nanobiotix's next earnings date?

The next earnings date currently listed for Nanobiotix (NASDAQ-NBTX) is September 30, 2026.

Does Nanobiotix (NASDAQ-NBTX) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Nanobiotix (NASDAQ-NBTX)?

The current P/E ratio listed for Nanobiotix (NASDAQ-NBTX) is -71.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Nanobiotix?

The current market capitalization listed for Nanobiotix is 1.812 B.

What is the enterprise value of Nanobiotix?

The current enterprise value listed for Nanobiotix is 2.055 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Nanobiotix?

The ticker symbol for Nanobiotix is NASDAQ-NBTX, and the stock is listed on NASDAQ.

Where is Nanobiotix (NASDAQ-NBTX) listed?

Nanobiotix (NASDAQ-NBTX) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Nanobiotix?

The current debt-to-total-capital ratio listed for Nanobiotix is 5.7%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Nanobiotix?

The free float listed for Nanobiotix is 65.8%. Free float helps investors understand how much of the share base is available for public trading.

Nanobiotix (NBTX) Fair Value & Stock Analysis

Nanobiotix (NBTX)

Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing cancer-related product candidates and therapies for other serious unmet medical needs. Its lead candidate, NBTXR3, is an investigational product based on crystalline hafnium oxide nanoparticles and is being studied across several cancer indications, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. The company also has a collaboration with Lian Oncology Limited to support development and commercialization of NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Founded in 2003, Nanobiotix is headquartered in Paris, France. The listed security is an ADR representing common stock of Nanobiotix on NASDAQ.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-NBTX	$26.76	-30.7% Downside	Overvalued	$43.78	13.4% Upside	Fair	Fair	—	—	—	0.0%	September 30, 2026	-71.2x	-20.2x	52.4x	1.812 B	2.055 B	5.7%	65.8%	0.9	—	141.7%